Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia

Leukemia Research

Volumn 37, Issue 7, 2013, Pages 747-751

  Leblebjian, Houry ^a   DeAngelo, Daniel J ^a   Skirvin, J Andrew ^a,b,d   Stone, Richard M ^a   Wadleigh, Martha ^a   Werner, Lillian ^a   Neuberg, Donna S ^a,c   Bartel, Sylvia ^a,d   McDonnell, Anne M ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; ATRA; Differentiation syndrome; Retinoic acid syndrome

Indexed keywords

ALLOPURINOL; ARSENIC TRIOXIDE; CEFTAZIDIME; CYTARABINE; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DAUNORUBICIN; DIPHENHYDRAMINE; ESOMEPRAZOLE; FLUCONAZOLE; FUROSEMIDE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; LORAZEPAM; OLANZAPINE; ONDANSETRON; OXYCODONE; PARACETAMOL; RETINOIC ACID; SIMVASTATIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; BLAST CELL; BODY MASS; CELL COUNT; DIFFERENTIATION SYNDROME; FEMALE; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RETINOIC ACID SYNDROME; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BODY MASS INDEX; CELL DIFFERENTIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; SYNDROME; TRETINOIN; YOUNG ADULT;

EID: 84878480252     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.04.011     Document Type: Article

References (35)

1. Breccia M., Lo-Coco F. Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. Expert Opin Pharmacother 2012, 13(7):1031-1043.
2. Powell B.L., Moser B., Stock W., et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010, 116(19):3751-3757.
3. Park J.H., Qiao B., Panageas K.S., et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011, 118(5):1248-1254.
4. de Botton S., Chevret S., Coiteux V., et al. Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. Leukemia 2003, 17(2):339-342.
5. Patatanian E., Thompson D.F. Retinoic acid syndrome: a review. J Clin Pharm Ther 2008, 33(4):331-338.
6. Frankel S.R., Eardley A., Lauwers G., Weiss M., Warrell R.P. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 1992, 117(4):292-296.
7. De Botton S., Dombret H., Sanz M., et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1998, 92(8):2712-2718.
8. Tallman M.S., Andersen J.W., Schiffer C.A., et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000, 95(1):90-95.
9. de la Serna J., Montesinos P., Vellenga E., et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008, 111(7):3395-3402.
10. Montesinos P., Bergua J.M., Vellenga E., et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009, 113(4):775-783.
11. Vahdat L., Maslak P., Miller W.H., et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994, 84(11):3843-3849.
12. Bruno R.D., Njar V.C. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem 2007, 15(15):5047-5060.
13. McSorley L.C., Daly A.K. Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. Biochem Pharmacol 2000, 60(4):517-526.
14. Series MH. In: Micromedex. Greenwod Village, Colorado; 2008, p. 119.
15. UpToDate. UpToDate Online: UpToDate.
16. Flockhart D. Drug interactions: cytochrome P450 drug interaction table 2007, Indiana University School of Medicine.
17. Cheson B.D., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21(24):4642-4649.
18. Sanz M.A., Martin G., Gonzalez M., et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004, 103(4):1237-1243.
19. Cortes J.E., Kantarjian H., O'Brien S., et al. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer 1994, 73(12):2946-2952.
20. Kanamaru A., Takemoto Y., Tanimoto M., et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 1995, 85(5):1202-1206.
21. Jeddi R., Ghedira H., Mnif S., Gouider E., Fenaux P., Meddeb B. High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res 2010, 34(4):545-547.
22. Jeddi R., Kacem K., Ben Neji H., et al. Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia. Hematology 2008, 13(3):142-146.
23. Frankel S.R., Eardley A., Heller G., et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med 1994, 120(4):278-286.
24. Lee J.S., Newman R.A., Lippman S.M., et al. Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors. J Clin Oncol 1995, 13(6):1501-1508.
25. Van Wauwe J.P., Coene M.C., Goossens J., Van Nijen G., Cools W., Lauwers W. Ketoconazole inhibits the in vitro and in vivo metabolism of all-trans-retinoic acid. J Pharmacol Exp Ther 1988, 245(2):718-722.
26. Adamson P.C. All-trans-retinoic acid pharmacology and its impact on the treatment of acute promyelocytic leukemia. Oncologist 1996, 1(5):305-314.
27. Rigas J.R., Francis P.A., Muindi J.R., et al. Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. J Natl Cancer Inst 1993, 85(23):1921-1926.
28. Dixon K.S., Hassoun A. Pseudotumor cerebri due to the potentiation of all-trans retinoic acid by voriconazole. J Am Pharm Assoc (2003) 2010, 50(6):742-744.
29. Vanier K.L., Mattiussi A.J., Johnston D.L. Interaction of all-trans-retinoic acid with fluconazole in acute promyelocytic leukemia. J Pediatr Hematol Oncol 2003, 25(5):403-404.
30. Rizvi N.A., Marshall J.L., Ness E., et al. Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer. Clin Cancer Res 1998, 4(6):1437-1442.
31. Cordoba R., Ramirez E., Lei S.H., et al. Hypercalcemia due to an interaction of all-trans retinoic acid (ATRA) and itraconazole therapy for acute promyelocytic leukemia successfully treated with zoledronic acid. Eur J Clin Pharmacol 2008, 64(10):1031-1032.
32. Breccia M., Mazzarella L., Bagnardi V., et al. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. Blood 2012, 119(1):49-54.
33. Konopleva M., Mikhail A., Estrov Z., et al. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood 1999, 93(5):1668-1676.
34. Tabe Y., Konopleva M., Munsell M.F., et al. PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood 2004, 103(5):1815-1822.
35. Sanz M.A., Lo Coco F., Martin G., et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000, 96(4):1247-1253.